ASCO Annual Meeting | Conference

Analysts, Companies Highlight Key ASCO Research

June 1st 2012

Pharmaceutical industry analysts and companies have been weighing in on their selections for the most noteworthy research to be presented during the 2012 ASCO Annual Meeting.

2012 ASCO Pre-Meeting Video Coverage

May 31st 2012

American Society of Clinical Oncology (ASCO) 2012 Annual Meeting video highlights, from OncLive TV.

Advanced Coverage Recap: 2012 ASCO Annual Meeting

May 30th 2012

On May 16, the ASCO highlighted the results of five ground-breaking studies in advance of its annual meeting held in Chicago from June 1-5, 2012.

Dr. Goy Highlights Research From the 2012 ASCO Meeting

May 30th 2012

Dr. Andre Goy, from John Theurer Cancer Center, Highlights Research From the 2012 ASCO Meeting.

Dr. Gomella on the Unique Attributes of Neoadjuvant Zytiga

May 30th 2012

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, on the Unique Attributes of Neoadjuvant Zytiga.

Dr. Markman on Long-Term Chemotherapy Side Effects

May 29th 2012

Dr. Maurie Markman, from Cancer Treatment Centers of America, on Awareness of Long-Term Chemotherapy Side Effects

Dr. Goy on Neoadjuvant Hormonal Therapy Plus Zytiga

May 18th 2012

Dr. Andrew Goy, from John Theurer Cancer Center, on Neoadjuvant Hormonal Therapy Plus Zytiga

Dr. Rotkowitz on the Dabrafenib/Trametinib Combination

May 17th 2012

Dr. Michael Rotkowitz, from Cancer Treatment Centers of America, on the Dabrafenib Plus Trametinib Combination for Melanoma

Neoadjuvant Zytiga Helps Eliminate Some Patients' Prostate Tumors

May 16th 2012

Combined neoadjuvant treatment with abiraterone acetate (Zytiga) plus standard hormonal therapy before prostatectomy eradicated or nearly eradicated tumors in 34% of patients with localized high-risk prostate cancer.

Combining Two Targeted Therapies Stalls Disease Progression in Melanoma Patients With BRAF Mutations

May 16th 2012

A combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib has shown promising activity in patients with advanced melanoma.

Olanzapine Proves Effective in Breakthrough CINV

May 16th 2012

Olanzapine, an antipsychotic medication that is often used off-label, has proved highly effective in controlling breakthrough chemotherapy-induced nausea and vomiting.

Dr. Gomella on Neoadjuvant Hormonal Therapy Plus Zytiga

May 16th 2012

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, on Neoadjuvant Hormonal Therapy Combined With Abiraterone Acetate

Dr. Chapman on BRAF/MEK Combination for Melanoma

May 16th 2012

Dr. Paul Chapman, from Memorial Sloan-Kettering Cancer Center, on Combining BRAF and MEK Inhibitors for Advanced Melanoma

Dr. Markman on PCP Awareness of Long-Term Side Effects

May 16th 2012

Dr. Maurie Markman, Cancer Treatment Centers of America, on Primary Care Physician Awareness of Long-Term Chemotherapy Side Effects

PCPs Highly Unaware of Long-Term Chemotherapy Side Effects

May 16th 2012

Many primary care providers and some oncologists are unaware of the long-term effects of four chemotherapy drugs used to treat two of the most common forms of cancer.

Dr. Goy on Crizotinib for Pediatric Patients With ALCL

May 16th 2012

Dr. Andre Goy, from John Theurer Cancer Center, on Crizotinib for Pediatric Patients With ALCL

Crizotinib Active in ALK-Positive Pediatric Cancers

May 16th 2012

Targeting the ALK gene with the oral agent crizotinib slowed or eliminated signs of tumor growth in pediatric patients with aggressive forms of neuroblastoma, ALCL, and IMTs.

Dr. Kazmi Discusses Olanzapine for Breakthrough CINV

May 16th 2012

Dr. Shayma Kazmi, from Cancer Treatment Centers of America, on Olanzapine for Breakthrough Chemotherapy-Induced Nausea and Vomiting

Preview: 2012 ASCO Annual Meeting Coverage

March 26th 2012

OncLive.com will be on-site at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting.

ASCO 2011 Annual Meeting Daily Picture Slideshows

June 8th 2011

American Society of Clinical Oncology (ASCO) 2011 Annual Meeting Daily Picture Slideshow